Literature DB >> 30128742

[Basal cell carcinoma of the face and scalp : An update on treatment options].

B Frerich1, F Prall2.   

Abstract

The treatment of malignant tumors of the facial skin is an important part of the specialty oral and maxillofacial surgery. In two successive CME articles, important aspects of frequent entities are dealt with for the facial area. The current article deals with basal cell carcinoma, the most common localization of which is by far the facial area. Surgical resection is the treatment modality of first choice. A risk-adapted approach involving complete histopathological margin assessment is recommended for basal cell carcinoma at risk for recurrence or aggressive spread in order to spare healthy skin and to control subclinical tumor growth. There are specific caveats for non-surgical treatment options, such as topical medication, destructive procedures, and radiotherapy. This article describes indications and treatment methods with a focus on surgical resection techniques.

Entities:  

Keywords:  Histological techniques; Margins of excision; Micrographic surgery; Skin neoplasms; Skin neoplasms/pathology; Skin neoplasms/surgery

Mesh:

Year:  2018        PMID: 30128742     DOI: 10.1007/s00292-018-0486-y

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  30 in total

1.  [The Muffin technique--an alternative to Mohs' micrographic surgery].

Authors:  Matthias Möhrle; Helmut Breuninger
Journal:  J Dtsch Dermatol Ges       Date:  2006-12       Impact factor: 5.584

2.  Recurrence rates of treated basal cell carcinomas. Part 1: Overview.

Authors:  M K Silverman; A W Kopf; C M Grin; R S Bart; M J Levenstein
Journal:  J Dermatol Surg Oncol       Date:  1991-09

3.  Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients.

Authors:  Armand B Cognetta; Brett M Howard; Henry P Heaton; Earl R Stoddard; Hyokyoung Grace Hong; W Harris Green
Journal:  J Am Acad Dermatol       Date:  2012-07-19       Impact factor: 11.527

4.  Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).

Authors:  Gina P Kwon; Mina Sarah Ally; Irene Bailey-Healy; Anthony E Oro; Jinah Kim; Anne Lynn Chang; Sumaira Aasi; Jean Y Tang
Journal:  J Am Acad Dermatol       Date:  2016-07       Impact factor: 11.527

5.  Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial.

Authors:  Fiona Bath-Hextall; Mara Ozolins; Sarah J Armstrong; Graham B Colver; William Perkins; Paul S J Miller; Hywel C Williams
Journal:  Lancet Oncol       Date:  2013-12-11       Impact factor: 41.316

6.  Predicting recurrence of basal-cell carcinomas treated by microscopically controlled excision: a recurrence index score.

Authors:  D S Rigel; P Robins; R J Friedman
Journal:  J Dermatol Surg Oncol       Date:  1981-10

7.  Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients.

Authors:  David G Lott; Ryan Manz; Carl Koch; Robert R Lorenz
Journal:  Transplantation       Date:  2010-09-27       Impact factor: 4.939

8.  Factors affecting the recurrence rate of basal cell carcinoma.

Authors:  Fie Saabye Bøgelund; Peter Ashlede Philipsen; Robert Gniadecki
Journal:  Acta Derm Venereol       Date:  2007       Impact factor: 4.437

9.  Incomplete removal of basal cell carcinoma: what is the value of further surgery?

Authors:  Shiralee S Patel; Sandeep H Cliff; Peter Ward Booth
Journal:  Oral Maxillofac Surg       Date:  2012-08-07

10.  Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes.

Authors:  Alejandro Tormo; Francisco Celada; Silvia Rodriguez; Rafael Botella; Antonio Ballesta; Michael Kasper; Zoubir Ouhib; Manuel Santos; Jose Perez-Calatayud
Journal:  J Contemp Brachytherapy       Date:  2014-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.